Nanocarrier-Mediated Immunogenic Cell Death for Melanoma Treatment

References

• Gallicchio L, Devasia TP, Tonorezos E, Mollica MA, Mariotto A. Estimation of the Number of Individuals Living With Metastatic Cancer in the United States. J Natl Cancer Inst. 2022;114(11):1476–1483. doi:10.1093/jnci/djac158
   PubMedGoogle Scholar
• Diep YN, Kim TJ, Cho H, Lee LP. Nanomedicine for advanced cancer immunotherapy. J Control Release. 2022;351:1017–1037. doi:10.1016/j.jconrel.2022.10.004
   PubMed Web of Science ®Google Scholar
• Guo ZS. The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer). BMC Cancer. 2018;18(1):1086. doi:10.1186/s12885-018-5020-3
   PubMedGoogle Scholar
• Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002–1014. doi:10.1016/S0140-6736(21)01206-X
   PubMed Web of Science ®Google Scholar
• Milone MC, Xu J, Chen SJ, et al. Author Correction: engineering-enhanced CAR T cells for improved cancer therapy. Nat Cancer. 2021;2(10):1113. doi:10.1038/s43018-021-00277-7
   PubMedGoogle Scholar
• Lim WA, June CH. The Principles of Engineering Immune Cells to Treat Cancer. Cell. 2017;168(4):724–740. doi:10.1016/j.cell.2017.01.016
   PubMed Web of Science ®Google Scholar
• Huang K, Liu X, Han G, Zhou Y. Nano-optogenetic immunotherapy. Clin Transl Med. 2022;12(9):e1020. doi:10.1002/ctm2.1020
   PubMed Web of Science ®Google Scholar
• Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol. 2016;39:1–6. doi:10.1016/j.coi.2015.10.009
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487–500. doi:10.1038/s41590-022-01132-2
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61. doi:10.1038/nm1523
   PubMed Web of Science ®Google Scholar
• Yatim N, Cullen S, Albert ML. Dying cells actively regulate adaptive immune responses. Nat Rev Immunol. 2017;17(4):262–275. doi:10.1038/nri.2017.9
   PubMed Web of Science ®Google Scholar
• Hayashi K, Nikolos F, Lee YC, et al. Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. Nat Commun. 2020;11(1):6299. doi:10.1038/s41467-020-19970-9
   PubMed Web of Science ®Google Scholar
• Jin MZ, Wang XP. Immunogenic Cell Death-Based Cancer Vaccines. Front Immunol. 2021;12:697964. doi:10.3389/fimmu.2021.697964
   PubMed Web of Science ®Google Scholar
• Bonaventura P, Shekarian T, Alcazer V, et al. Cold Tumors: a Therapeutic Challenge for Immunotherapy. Front Immunol. 2019;10:168. doi:10.3389/fimmu.2019.00168
   PubMed Web of Science ®Google Scholar
• Kim DY, Pyo A, Yun M, et al. Imaging Calreticulin for Early Detection of Immunogenic Cell Death During Anticancer Treatment. J Nucl Med. 2021;62(7):956–960. doi:10.2967/jnumed.120.245290
   PubMed Web of Science ®Google Scholar
• Michaud M, Martins I, Sukkurwala AQ, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334(6062):1573–1577. doi:10.1126/science.1208347
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vitale I, Martins I, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science. 2012;337(6102):1678–1684. doi:10.1126/science.1224922
   PubMed Web of Science ®Google Scholar
• Ma Y, Adjemian S, Mattarollo SR, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38(4):729–741. doi:10.1016/j.immuni.2013.03.003
   PubMed Web of Science ®Google Scholar
• Johnson S, Michalak M, Opas M, Eggleton P. The ins and outs of calreticulin: from the ER lumen to the extracellular space. Trends Cell Biol. 2001;11(3):122–129. doi:10.1016/s0962-8924(01)01926-2
   PubMed Web of Science ®Google Scholar
• Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14(12):2994–3006. doi:10.1002/1878-0261.12851
   PubMed Web of Science ®Google Scholar
• Bezu L, Sauvat A, Humeau J, et al. eIF2alpha phosphorylation is pathognomonic for immunogenic cell death. Cell Death Differ. 2018;25(8):1375–1393. doi:10.1038/s41418-017-0044-9
   PubMed Web of Science ®Google Scholar
• Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med. 2005;201(7):1135–1143. doi:10.1084/jem.20042614
   PubMed Web of Science ®Google Scholar
• Yu M, Wang H, Ding A, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006;26(2):174–179. doi:10.1097/01.shk.0000225404.51320.82
   PubMed Web of Science ®Google Scholar
• Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta. 2010;1805(1):53–71. doi:10.1016/j.bbcan.2009.08.003
   PubMed Web of Science ®Google Scholar
• Son M, Porat A, He M, et al. C1q and HMGB1 reciprocally regulate human macrophage polarization. Blood. 2016;128(18):2218–2228. doi:10.1182/blood-2016-05-719757
   PubMed Web of Science ®Google Scholar
• Bianchi ME, Crippa MP, Manfredi AA, Mezzapelle R, Rovere Querini P, Venereau E. High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair. Immunol Rev. 2017;280(1):74–82. doi:10.1111/imr.12601
   PubMed Web of Science ®Google Scholar
• Li DY, Liang S, Wen JH, Tang JX, Deng SL, Liu YX. Extracellular HSPs: the Potential Target for Human Disease Therapy. Molecules. 2022;27(7):2361. doi:10.3390/molecules27072361
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jing J, Ye Y, et al. Characterization of the dual functional effects of heat shock proteins (HSPs) in cancer hallmarks to aid development of HSP inhibitors. Genome Med. 2020;12(1):101. doi:10.1186/s13073-020-00795-6
   PubMed Web of Science ®Google Scholar
• Lanneau D, Brunet M, Frisan E, Solary E, Fontenay M, Garrido C. Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med. 2008;12(3):743–761. doi:10.1111/j.1582-4934.2008.00273.x
   PubMed Web of Science ®Google Scholar
• Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15(1):3–12. doi:10.1038/sj.cdd.4402269
   PubMed Web of Science ®Google Scholar
• Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood. 2007;109(11):4839–4845. doi:10.1182/blood-2006-10-054221
   PubMed Web of Science ®Google Scholar
• Blaschke T, Burnett C, Pekkarinen A. Image Segmentation Methods for Object-based Analysis and Classification. In: Jong SMD, Meer F, editors. Remote Sensing Image Analysis: Including the Spatial Domain. Springer Netherlands; 2004:211–236.
   Google Scholar
• Xia H, Green DR, Zou W. Autophagy in tumour immunity and therapy. Nat Rev Cancer. 2021;21(5):281–297. doi:10.1038/s41568-021-00344-2
   PubMed Web of Science ®Google Scholar
• Martins I, Wang Y, Michaud M, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 2014;21(1):79–91. doi:10.1038/cdd.2013.75
   PubMed Web of Science ®Google Scholar
• Wang Y, Martins I, Ma Y, Kepp O, Galluzzi L, Kroemer G. Autophagy-dependent ATP release from dying cells via lysosomal exocytosis. Autophagy. 2013;9(10):1624–1625. doi:10.4161/auto.25873
   PubMed Web of Science ®Google Scholar
• Muller T, Robaye B, Vieira RP, et al. The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. Allergy. 2010;65(12):1545–1553. doi:10.1111/j.1398-9995.2010.02426.x
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Liu H, Edward Zhou X, et al. Structure of formylpeptide receptor 2-G(i) complex reveals insights into ligand recognition and signaling. Nat Commun. 2020;11(1):885. doi:10.1038/s41467-020-14728-9
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Ma Y, Baracco EE, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015;350(6263):972–978. doi:10.1126/science.aad0779
   PubMed Web of Science ®Google Scholar
• Baracco EE, Stoll G, Van Endert P, Zitvogel L, Vacchelli E, Kroemer G. Contribution of annexin A1 to anticancer immunosurveillance. Oncoimmunology. 2019;8(11):e1647760. doi:10.1080/2162402X.2019.1647760
   PubMed Web of Science ®Google Scholar
• Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115. doi:10.1038/s41573-018-0004-1
   PubMed Web of Science ®Google Scholar
• Liu T, Han C, Wang S, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12(1):86. doi:10.1186/s13045-019-0770-1
   PubMed Web of Science ®Google Scholar
• Vandyck HH, Hillen LM, Bosisio FM, van den Oord J, Zur Hausen A, Winnepenninckx V. Rethinking the biology of metastatic melanoma: a holistic approach. Cancer Metastasis Rev. 2021;40(2):603–624. doi:10.1007/s10555-021-09960-8
   PubMed Web of Science ®Google Scholar
• Masaoutis C, Kokkali S, Theocharis S. Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment. Expert Opin Investig Drugs. 2021;30(5):555–569. doi:10.1080/13543784.2021.1898587
   PubMed Web of Science ®Google Scholar
• Cockram TOJ, Dundee JM, Popescu AS, Brown GC. The Phagocytic Code Regulating Phagocytosis of Mammalian Cells. Front Immunol. 2021;12:629979. doi:10.3389/fimmu.2021.629979
   PubMed Web of Science ®Google Scholar
• Nguyen T, Kocovski N, Macdonald S, Yeang HXA, Wang M, Neeson PJ. Multiplex Immunohistochemistry Analysis of Melanoma Tumor-Infiltrating Lymphocytes. Methods Mol Biol. 2021;2265:557–572. doi:10.1007/978-1-0716-1205-7_39
   PubMedGoogle Scholar
• Bernal-Estevez DA, Ortiz Barbosa MA, Ortiz-Montero P, Cifuentes C, Sanchez R, Parra-Lopez CA. Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: a Single-Arm Phase I/II Trial. Front Immunol. 2021;12:669965. doi:10.3389/fimmu.2021.669965
   PubMed Web of Science ®Google Scholar
• Zhao J, Huang H, Zhao J, et al. A hybrid bacterium with tumor-associated macrophage polarization for enhanced photothermal-immunotherapy. Acta Pharm Sin B. 2022;12(6):2683–2694. doi:10.1016/j.apsb.2021.10.019
   PubMed Web of Science ®Google Scholar
• Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res. 2013;19(22):6074–6083. doi:10.1158/1078-0432.CCR-12-2603
   PubMed Web of Science ®Google Scholar
• De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 2013;23(3):277–286. doi:10.1016/j.ccr.2013.02.013
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61. doi:10.1016/j.immuni.2014.06.010
   PubMed Web of Science ®Google Scholar
• Han S, Wang W, Wang S, et al. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes. Theranostics. 2021;11(6):2892–2916. doi:10.7150/thno.50928
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369–382. doi:10.1038/s41577-019-0127-6
   PubMed Web of Science ®Google Scholar
• Li X, Pan J, Li Y, et al. Development of a Localized Drug Delivery System with a Step-by-Step Cell Internalization Capacity for Cancer Immunotherapy. ACS Nano. 2022;16(4):5778–5794. doi:10.1021/acsnano.1c10892
   PubMed Web of Science ®Google Scholar
• Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med. 2005;202(2):203–207. doi:10.1084/jem.20050810
   PubMed Web of Science ®Google Scholar
• Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563–604. doi:10.1146/annurev-immunol-020711-074950
   PubMed Web of Science ®Google Scholar
• Ma Y, Pitt JM, Li Q, Yang H. The renaissance of anti-neoplastic immunity from tumor cell demise. Immunol Rev. 2017;280(1):194–206. doi:10.1111/imr.12586
   PubMed Web of Science ®Google Scholar
• Ma Y, Mattarollo SR, Adjemian S, et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res. 2014;74(2):436–445. doi:10.1158/0008-5472.CAN-13-1265
   PubMed Web of Science ®Google Scholar
• Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114(2):280–290. doi:10.1172/JCI21583
   PubMed Web of Science ®Google Scholar
• Goc J, Germain C, Vo-Bourgais TK, et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2014;74(3):705–715. doi:10.1158/0008-5472.CAN-13-1342
   PubMed Web of Science ®Google Scholar
• He Z, Zhou H, Zhang Y, et al. Oxygen-boosted biomimetic nanoplatform for synergetic phototherapy/ferroptosis activation and reversal of immune-suppressed tumor microenvironment. Biomaterials. 2022;290:121832. doi:10.1016/j.biomaterials.2022.121832
   PubMed Web of Science ®Google Scholar
• Jiao X, Sun L, Zhang W, et al. Engineering oxygen-deficient ZrO(2-x) nanoplatform as therapy-activated “immunogenic cell death (ICD)” inducer to synergize photothermal-augmented sonodynamic tumor elimination in NIR-II biological window. Biomaterials. 2021;272:120787. doi:10.1016/j.biomaterials.2021.120787
   PubMed Web of Science ®Google Scholar
• Zuo W, Fan Z, Chen L, et al. Copper-based theranostic nanocatalysts for synergetic photothermal-chemodynamic therapy. Acta Biomater. 2022;147:258–269. doi:10.1016/j.actbio.2022.05.030
   PubMed Web of Science ®Google Scholar
• Meneveau MO, Sahli ZT, Lynch KT, Mauldin IS, Slingluff CL Jr. Immunotyping and Quantification of Melanoma Tumor-Infiltrating Lymphocytes. Methods Mol Biol. 2021;2265:515–528. doi:10.1007/978-1-0716-1205-7_36
   PubMedGoogle Scholar
• Kishton RJ, Sukumar M, Restifo NP. Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab. 2017;26(1):94–109. doi:10.1016/j.cmet.2017.06.016
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–1059. doi:10.1038/nm1622
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. doi:10.1146/annurev-immunol-032712-100008
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432–1433. doi:10.1126/science.342.6165.1432
   PubMed Web of Science ®Google Scholar
• Wiede F, Lu KH, Du X, et al. PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. Cancer Discov. 2022;12(3):752–773. doi:10.1158/2159-8290.CD-21-0694
   PubMed Web of Science ®Google Scholar
• Juneja VR, McGuire KA, Manguso RT, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214(4):895–904. doi:10.1084/jem.20160801
   PubMed Web of Science ®Google Scholar
• Cassano R, Cuconato M, Calviello G, Serini S, Trombino S. Recent Advances in Nanotechnology for the Treatment of Melanoma. Molecules. 2021;26(4):785. doi:10.3390/molecules26040785
   PubMed Web of Science ®Google Scholar
• Song M, Liu C, Chen S, Zhang W. Nanocarrier-Based Drug Delivery for Melanoma Therapeutics. Int J Mol Sci. 2021;22(4):1873. doi:10.3390/ijms22041873
   PubMed Web of Science ®Google Scholar
• Rautaniemi K, Zini J, Lofman E, et al. Addressing challenges in the removal of unbound dye from passively labelled extracellular vesicles. Nanoscale Adv. 2021;4(1):226–240. doi:10.1039/d1na00755f
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015;28(6):690–714. doi:10.1016/j.ccell.2015.10.012
   PubMed Web of Science ®Google Scholar
• Florencio KGD, Edson EA, Fernandes K, et al. Chromomycin A(5) induces bona fide immunogenic cell death in melanoma. Front Immunol. 2022;13:941757. doi:10.3389/fimmu.2022.941757
   PubMed Web of Science ®Google Scholar
• Lu Y, Ma X, Chang X, et al. Recent development of gold(I) and gold(III) complexes as therapeutic agents for cancer diseases. Chem Soc Rev. 2022;51(13):5518–5556. doi:10.1039/d1cs00933h
   PubMed Web of Science ®Google Scholar
• Guo J, Yu Z, Das M, Huang L. Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis. ACS Nano. 2020;14(4):5075–5089. doi:10.1021/acsnano.0c01676
   PubMed Web of Science ®Google Scholar
• Li L, Li Y, Yang CH, et al. Inhibition of Immunosuppressive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking. Adv Funct Mater. 2020;30(12):9081. doi:10.1002/adfm.201908961
   Web of Science ®Google Scholar
• Kuai R, Yuan W, Son S, et al. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Sci Adv. 2018;4(4):eaao1736. doi:10.1126/sciadv.aao1736
   PubMed Web of Science ®Google Scholar
• Meng F, Wang J, He Y, et al. A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces antitumor immunity. Proc Natl Acad Sci U S A. 2022;119(22):e2122595119. doi:10.1073/pnas.2122595119
   PubMed Web of Science ®Google Scholar
• Hu M et al . (2021). Immunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for cancer ImmunochemotherapyImmunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for cancer immunochemotherapy. Acs Nano, 15(2), 3123–3138. 10.1021/acsnano.0c0968110.1021/acsnano.0c09681.s001
   PubMed Web of Science ®Google Scholar
• Zhu M, Yang M, Zhang J, et al. Immunogenic Cell Death Induction by Ionizing Radiation. Front Immunol. 2021;12:705361. doi:10.3389/fimmu.2021.705361
   PubMed Web of Science ®Google Scholar
• Knijnenburg TA, Wang L, Zimmermann MT, et al. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep. 2018;23(1):239–254 e6. doi:10.1016/j.celrep.2018.03.076
   PubMed Web of Science ®Google Scholar
• McLaughlin M, Patin EC, Pedersen M, et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020;20(4):203–217. doi:10.1038/s41568-020-0246-1
   PubMed Web of Science ®Google Scholar
• Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548(7668):466–470. doi:10.1038/nature23470
   PubMed Web of Science ®Google Scholar
• Welsh J, Bevelacqua JJ, Dobrzyński L. Abscopal Effect Following Radiation Therapy in Cancer Patients: a New Look from the Immunological Point of View. J Biomed Phys Eng. 2020;10(4):537–542. doi:10.31661/jbpe.v0i0.1066
   PubMedGoogle Scholar
• Diamond JM, Vanpouille-Box C, Spada S, et al. Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs. Cancer Immunol Res. 2018;6(8):910–920. doi:10.1158/2326-6066.CIR-17-0581
   PubMed Web of Science ®Google Scholar
• Zhou Z, Ni K, Deng H, Chen X. Dancing with reactive oxygen species generation and elimination in nanotheranostics for disease treatment. Adv Drug Deliv Rev. 2020;158:73–90. doi:10.1016/j.addr.2020.06.006
   PubMed Web of Science ®Google Scholar
• Zhang M, Song R, Liu Y, et al. Calcium-Overload-Mediated Tumor Therapy by Calcium Peroxide Nanoparticles. Chem. 2019;5(8):2171–2182. doi:10.1016/j.chempr.2019.06.003
   Web of Science ®Google Scholar
• Sia J, Szmyd R, Hau E, Gee HE. Molecular Mechanisms of Radiation-Induced Cancer Cell Death: a Primer. Front Cell Dev Biol. 2020;8:41. doi:10.3389/fcell.2020.00041
   PubMed Web of Science ®Google Scholar
• Huang Y, Dong Y, Zhao J, Zhang L, Kong L, Lu JJ. Comparison of the effects of photon, proton and carbon-ion radiation on the ecto-calreticulin exposure in various tumor cell lines. Ann Transl Med. 2019;7(20):542. doi:10.21037/atm.2019.09.128
   PubMed Web of Science ®Google Scholar
• Snyder AG, Hubbard NW, Messmer MN, et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci Immunol. 2019;4(36):2004. doi:10.1126/sciimmunol.aaw2004
   Web of Science ®Google Scholar
• Wang HH, Wu ZQ, Qian D, et al. Ablative Hypofractionated Radiation Therapy Enhances Non-Small Cell Lung Cancer Cell Killing via Preferential Stimulation of Necroptosis In Vitro and In Vivo. Int J Radiat Oncol Biol Phys. 2018;101(1):49–62. doi:10.1016/j.ijrobp.2018.01.036
   PubMed Web of Science ®Google Scholar
• Huang Z, Wang Y, Yao D, Wu J, Hu Y, Yuan A. Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress. Nat Commun. 2021;12(1):145. doi:10.1038/s41467-020-20243-8
   PubMed Web of Science ®Google Scholar
• Wang Y, Ding Y, Yao D, et al. Copper-Based Nanoscale Coordination Polymers Augmented Tumor Radioimmunotherapy for Immunogenic Cell Death Induction and T-Cell Infiltration. Small. 2021;17(8):e2006231. doi:10.1002/smll.202006231
   PubMed Web of Science ®Google Scholar
• Zheng P, Ding B, Jiang Z, et al. Ultrasound-Augmented Mitochondrial Calcium Ion Overload by Calcium Nanomodulator to Induce Immunogenic Cell Death. Nano Lett. 2021;21(5):2088–2093. doi:10.1021/acs.nanolett.0c04778
   PubMed Web of Science ®Google Scholar
• Alzeibak R, Mishchenko TA, Shilyagina NY, Balalaeva IV, Krysko DV. Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. J Immunother Cancer. 2021;9(1). doi:10.1136/jitc-2020-001926
   PubMed Web of Science ®Google Scholar
• He C, Duan X, Guo N, et al. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat Commun. 2016;7:12499. doi:10.1038/ncomms12499
   PubMed Web of Science ®Google Scholar
• Chen C, Ni X, Jia S, et al. Massively Evoking Immunogenic Cell Death by Focused Mitochondrial Oxidative Stress using an AIE Luminogen with a Twisted Molecular Structure. Adv Mater. 2019;31(52):e1904914. doi:10.1002/adma.201904914
   PubMed Web of Science ®Google Scholar
• Yang G, Lu SB, Li C, et al. Type I macrophage activator photosensitizer against hypoxic tumors. Chem Sci. 2021;12(44):14773–14780. doi:10.1039/d1sc04124j
   PubMed Web of Science ®Google Scholar
• Mao D, Hu F, Yi Z, et al. AIEgen-coupled upconversion nanoparticles eradicate solid tumors through dual-mode ROS activation. Sci Adv. 2020;6(26):eabb2712. doi:10.1126/sciadv.abb2712
   PubMed Web of Science ®Google Scholar
• Chen Z, Liu L, Liang R, et al. Bioinspired Hybrid Protein Oxygen Nanocarrier Amplified Photodynamic Therapy for Eliciting Anti-tumor Immunity and Abscopal Effect. ACS Nano. 2018;12(8):8633–8645. doi:10.1021/acsnano.8b04371
   PubMed Web of Science ®Google Scholar
• Ding Y, Sun Z, Gao Y, et al. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway. Adv Mater. 2021;33(34):e2102188. doi:10.1002/adma.202102188
   PubMed Web of Science ®Google Scholar
• Liu D, Chen B, Mo Y, et al. Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway. Nano Lett. 2019;19(10):6964–6976. doi:10.1021/acs.nanolett.9b02306
   PubMed Web of Science ®Google Scholar
• Yang W, Zhang F, Deng H, et al. Smart Nanovesicle-Mediated Immunogenic Cell Death through Tumor Microenvironment Modulation for Effective Photodynamic Immunotherapy. ACS Nano. 2020;14(1):620–631. doi:10.1021/acsnano.9b07212
   PubMed Web of Science ®Google Scholar
• Wang Y, Meng HM, Li Z. Near-infrared inorganic nanomaterial-based nanosystems for photothermal therapy. Nanoscale. 2021;13(19):8751–8772. doi:10.1039/d1nr00323b
   PubMed Web of Science ®Google Scholar
• Wu D, Zhou J, Chen X, et al. Mesoporous polydopamine with built-in plasmonic core: traceable and NIR triggered delivery of functional proteins. Biomaterials. 2020;238:119847. doi:10.1016/j.biomaterials.2020.119847
   PubMed Web of Science ®Google Scholar
• Zhu Y, Hoh HY, Qian S, et al. Ultrastable Zinc Anode Enabled by CO(2)-Induced Interface Layer. ACS Nano. 2022;16(9):14600–14610. doi:10.1021/acsnano.2c05124
   PubMed Web of Science ®Google Scholar
• Sweeney EE, Cano-Mejia J, Fernandes R. Photothermal Therapy Generates a Thermal Window of Immunogenic Cell Death in Neuroblastoma. Small. 2018;14(20):e1800678. doi:10.1002/smll.201800678
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang Y, Li X, et al. Near-Infrared II Phototherapy Induces Deep Tissue Immunogenic Cell Death and Potentiates Cancer Immunotherapy. ACS Nano. 2019;13(10):11967–11980. doi:10.1021/acsnano.9b06040
   PubMed Web of Science ®Google Scholar
• Xie L, Li J, Wang G, et al. Phototheranostic Metal-Phenolic Networks with Antiexosomal PD-L1 Enhanced Ferroptosis for Synergistic Immunotherapy. J Am Chem Soc. 2022;144(2):787–797. doi:10.1021/jacs.1c09753
   PubMed Web of Science ®Google Scholar
• Jiang Y, Huang J, Xu C, Pu K. Activatable polymer nanoagonist for second near-infrared photothermal immunotherapy of cancer. Nat Commun. 2021;12(1):742. doi:10.1038/s41467-021-21047-0
   PubMed Web of Science ®Google Scholar
• Shaterabadi Z, Nabiyouni G, Soleymani M. Physics responsible for heating efficiency and self-controlled temperature rise of magnetic nanoparticles in magnetic hyperthermia therapy. Prog Biophys Mol Biol. 2018;133:9–19. doi:10.1016/j.pbiomolbio.2017.10.001
   PubMed Web of Science ®Google Scholar
• El-Boubbou K. Magnetic iron oxide nanoparticles as drug carriers: clinical relevance. Nanomedicine. 2018;13(8):953–971. doi:10.2217/nnm-2017-0336
   PubMed Web of Science ®Google Scholar
• Stea B, Kittelson J, Cassady JR, et al. Treatment of malignant gliomas with interstitial irradiation and hyperthermia. Int J Radiat Oncol Biol Phys. 1992;24(4):657–667. doi:10.1016/0360-3016(92)90711-p
   PubMed Web of Science ®Google Scholar
• Deger S, Taymoorian K, Boehmer D, et al. Thermoradiotherapy using interstitial self-regulating thermoseeds: an intermediate analysis of a phase II trial. Eur Urol. 2004;45(5):574–579. doi:10.1016/j.eururo.2003.11.012
   PubMed Web of Science ®Google Scholar
• Liu X, Zheng J, Sun W, et al. Ferrimagnetic Vortex Nanoring-Mediated Mild Magnetic Hyperthermia Imparts Potent Immunological Effect for Treating Cancer Metastasis. ACS Nano. 2019;13(8):8811–8825. doi:10.1021/acsnano.9b01979
   PubMed Web of Science ®Google Scholar
• Adkins I, Sadilkova L, Hradilova N, Tomala J, Kovar M, Spisek R. Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells. Oncoimmunology. 2017;6(5):e1311433. doi:10.1080/2162402X.2017.1311433
   PubMed Web of Science ®Google Scholar
• Hergt R, Andra W, d’Ambly CG, et al. Physical limits of hyperthermia using magnetite fine particles. IEEE Trans Magn. 1998;34(5):3745–3754. doi:10.1109/20.718537
   Web of Science ®Google Scholar
• Jordan A, Scholz R, Wust P, Fähling H, Roland F. Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J Magn Magn Mater. 1999;201(1):413–419. doi:10.1016/S0304-8853(99)00088-8
   Google Scholar
• Jang JT, Lee J, Seon J, et al. Giant Magnetic Heat Induction of Magnesium-Doped gamma-Fe(2) O(3) Superparamagnetic Nanoparticles for Completely Killing Tumors. Adv Mater. 2018;30(6):56.
   Web of Science ®Google Scholar
• Liu X, Yan B, Li Y, et al. Graphene Oxide-Grafted Magnetic Nanorings Mediated Magnetothermodynamic Therapy Favoring Reactive Oxygen Species-Related Immune Response for Enhanced Antitumor Efficacy. ACS Nano. 2020;14(2):1936–1950. doi:10.1021/acsnano.9b08320
   PubMed Web of Science ®Google Scholar
• Heshmati Aghda N, Torres Hurtado S, Abdulsahib SM, Lara EJ, Tunnell JW, Betancourt T. Dual Photothermal/Chemotherapy of Melanoma Cells with Albumin Nanoparticles Carrying Indocyanine Green and Doxorubicin Leads to Immunogenic Cell Death. Macromol Biosci. 2022;22(2):e2100353. doi:10.1002/mabi.202100353
   PubMed Web of Science ®Google Scholar
• Konda P, Roque Iii JA, Lifshits LM, et al. Photodynamic therapy of melanoma with new, structurally similar, NIR-absorbing ruthenium (II) complexes promotes tumor growth control via distinct hallmarks of immunogenic cell death. Am J Cancer Res. 2022;12(1):210–228.
   PubMed Web of Science ®Google Scholar
• Liu X, Feng Y, Xu J, et al. Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade. J Control Release. 2021;332:194–209. doi:10.1016/j.jconrel.2021.02.020
   PubMed Web of Science ®Google Scholar
• Jia Y, Shi K, Dai L, et al. Gold Nanorods and Polymer Micelles Mediated Dual TLR Stimulators Delivery System CPG@Au NRs/M-R848 Regulate Macrophages Reprogramming and DC Maturation for Enhanced Photothermal Immunotherapy of Melanoma. Small Methods. 2023;7(5):e2201087. doi:10.1002/smtd.202201087
   PubMedGoogle Scholar
• Ma S, Liang X, Yang N, et al. Boosting cancer immunotherapy by biomineralized nanovaccine with ferroptosis-inducing and photothermal properties. Biomater Sci. 2023;11(2):518–532. doi:10.1039/d2bm01126c
   PubMed Web of Science ®Google Scholar
• Feng ZH, Li ZT, Zhang S, et al. A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle. Acta Biomater. 2021;136:495–507. doi:10.1016/j.actbio.2021.09.052
   PubMed Web of Science ®Google Scholar
• Liu Q, Chen F, Hou L, et al. Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma. ACS Nano. 2018;12(8):7812–7825. doi:10.1021/acsnano.8b01890
   PubMed Web of Science ®Google Scholar
• Su Z, Xiao Z, Huang J, et al. Dual-Sensitive PEG-Sheddable Nanodrug Hierarchically Incorporating PD-L1 Antibody and Zinc Phthalocyanine for Improved Immuno-Photodynamic Therapy. ACS Appl Mater Interfaces. 2021;13(11):12845–12856. doi:10.1021/acsami.0c20422
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang J, Chen B, Ding X, Zhao N, Xu FJ. Rough Nanovaccines Boost Antitumor Immunity Through the Enhancement of Vaccination Cascade and Immunogenic Cell Death Induction. Small Methods. 2023;7(5):e2201595. doi:10.1002/smtd.202201595
   PubMedGoogle Scholar
• Li M, Guo R, Wei J, et al. Polydopamine-based nanoplatform for photothermal ablation with long-term immune activation against melanoma and its recurrence. Acta Biomater. 2021;136:546–557. doi:10.1016/j.actbio.2021.09.014
   PubMed Web of Science ®Google Scholar
• Yan T, Yang K, Chen C, et al. Synergistic photothermal cancer immunotherapy by Cas9 ribonucleoprotein-based copper sulfide nanotherapeutic platform targeting PTPN2. Biomaterials. 2021;279:121233. doi:10.1016/j.biomaterials.2021.121233
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guo C, Liu L, et al. ZnO-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death. Theranostics. 2020;10(24):11197–11214. doi:10.7150/thno.44920
   PubMed Web of Science ®Google Scholar
• Tang H, Xu X, Chen Y, et al. Reprogramming the Tumor Microenvironment through Second-Near-Infrared-Window Photothermal Genome Editing of PD-L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy. Adv Mater. 2021;33(12):e2006003. doi:10.1002/adma.202006003
   PubMed Web of Science ®Google Scholar
• Zhu J, Chang R, Wei B, et al. Photothermal Nano-Vaccine Promoting Antigen Presentation and Dendritic Cells Infiltration for Enhanced Immunotherapy of Melanoma via Transdermal Microneedles Delivery. Research (Wash D C). 2022;2022:9816272. doi:10.34133/2022/9816272
   PubMedGoogle Scholar
• Hu D, Xu H, Zhang W, et al. Vanadyl nanocomplexes enhance photothermia-induced cancer immunotherapy to inhibit tumor metastasis and recurrence. Biomaterials. 2021;277:121130. doi:10.1016/j.biomaterials.2021.121130
   PubMed Web of Science ®Google Scholar
• Li Z, Xiang J, Zhang Q, et al. An engineered hydrogel with low-dose antitumor drugs enhances tumor immunotherapy through tumor interstitial wrap. Front Bioeng Biotechnol. 2022;10:1072393. doi:10.3389/fbioe.2022.1072393
   PubMed Web of Science ®Google Scholar
• Medrano RFV, Salles TA, Dariolli R, et al. Potentiation of combined p19Arf and interferon-beta cancer gene therapy through its association with doxorubicin chemotherapy. Sci Rep. 2022;12(1):13636. doi:10.1038/s41598-022-17775-y
   PubMed Web of Science ®Google Scholar
• Yang C, Ming Y, Zhou K, et al. Macrophage Membrane-Camouflaged shRNA and Doxorubicin: a pH-Dependent Release System for Melanoma Chemo-Immunotherapy. Research (Wash D C). 2022;2022:9768687. doi:10.34133/2022/9768687
   PubMedGoogle Scholar
• Huang SW, Wang ST, Chang SH, et al. Imiquimod Exerts Antitumor Effects by Inducing Immunogenic Cell Death and Is Enhanced by the Glycolytic Inhibitor 2-Deoxyglucose. J Invest Dermatol. 2020;140(9):1771–1783 e6. doi:10.1016/j.jid.2019.12.039
   PubMed Web of Science ®Google Scholar
• Yu N, Ding M, Wang F, et al. Near-infrared photoactivatable semiconducting polymer nanocomplexes with bispecific metabolism interventions for enhanced cancer immunotherapy. Nano Today. 2022;46:101600. doi:10.1016/j.nantod.2022.101600
   Web of Science ®Google Scholar
• Su Z, Xiao Z, Wang Y, et al. Codelivery of Anti-PD-1 Antibody and Paclitaxel with Matrix Metalloproteinase and pH Dual-Sensitive Micelles for Enhanced Tumor Chemoimmunotherapy. Small. 2020;16(7):e1906832. doi:10.1002/smll.201906832
   PubMed Web of Science ®Google Scholar
• Yerragopu AK, Vellapandian C. Chemoimmunotherapy with doxorubicin and caffeine combination enhanced ICD induction and T-cell infiltration in B16F10 melanoma tumors. J Biochem Mol Toxicol. 2023;37(5):e23327. doi:10.1002/jbt.23327
   PubMedGoogle Scholar
• Wang C, Shi X, Song H, et al. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma. Biomaterials. 2021;268:120579. doi:10.1016/j.biomaterials.2020.120579
   PubMed Web of Science ®Google Scholar
• Fu X, Shi Y, Zang H, et al. Combination of oxaliplatin and POM-1 by nanoliposomes to reprogram the tumor immune microenvironment. J Control Release. 2022;347:1–13. doi:10.1016/j.jconrel.2022.04.041
   PubMed Web of Science ®Google Scholar
• Fan Y, Kuai R, Xu Y, Ochyl LJ, Irvine DJ, Moon JJ. Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy. Nano Lett. 2017;17(12):7387–7393. doi:10.1021/acs.nanolett.7b03218
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhu H, Tiruthani K, et al. Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma. ACS Nano. 2018;12(2):1250–1261. doi:10.1021/acsnano.7b07384
   PubMed Web of Science ®Google Scholar
• Shan CK, Du YB, Zhai XT, et al. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8(+) T cell augmentation. Cancer Chemother Pharmacol. 2021;87(3):425–436. doi:10.1007/s00280-020-04209-7
   PubMed Web of Science ®Google Scholar
• Li Q, Chen C, Kong J, Li L, Li J, Huang Y. Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade. Acta Pharm Sin B. 2022;12(5):2533–2549. doi:10.1016/j.apsb.2021.11.005
   PubMed Web of Science ®Google Scholar
• Li C, Zhang Y, Yan S, et al. Alternol triggers immunogenic cell death via reactive oxygen species generation. Oncoimmunology. 2021;10(1):1952539. doi:10.1080/2162402X.2021.1952539
   PubMed Web of Science ®Google Scholar
• Xie L, Wang G, Sang W, et al. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy. Biomaterials. 2021;269:120638. doi:10.1016/j.biomaterials.2020.120638
   PubMed Web of Science ®Google Scholar
• Gong Y, Chen M, Tan Y, et al. Injectable Reactive Oxygen Species-Responsive SN38 Prodrug Scaffold with Checkpoint Inhibitors for Combined Chemoimmunotherapy. ACS Appl Mater Interfaces. 2020;12(45):50248–50259. doi:10.1021/acsami.0c13943
   PubMed Web of Science ®Google Scholar
• Prieto K, Cao Y, Mohamed E, et al. Polyphenol-rich extract induces apoptosis with immunogenic markers in melanoma cells through the ER stress-associated kinase PERK. Cell Death Discov. 2019;5:134. doi:10.1038/s41420-019-0214-2
   PubMed Web of Science ®Google Scholar
• Yang C, He B, Zheng Q, et al. Nano-encapsulated tryptanthrin derivative for combined anticancer therapy via inhibiting indoleamine 2,3-dioxygenase and inducing immunogenic cell death. Nanomedicine. 2019;14(18):2423–2440. doi:10.2217/nnm-2019-0074
   PubMed Web of Science ®Google Scholar
• Kalus P, De Munck J, Vanbellingen S, et al. Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1(+) Myeloid Dendritic Cells. Int J Mol Sci. 2022;23(9):2165. doi:10.3390/ijms23094865
   PubMed Web of Science ®Google Scholar
• Zhou B, Shi B, Jin D, Liu X. Controlling upconversion nanocrystals for emerging applications. Nat Nanotechnol. 2015;10(11):924–936. doi:10.1038/nnano.2015.251
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–2532. doi:10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar